FDA
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
-
-
-
-
-
-
-
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence
-
-
-
-
-
-
-
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
-
330,375 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

